In summary, our findings demonstrated that YTHDC2 contributes to breast cancer progression by regulating the expression of stemness transcription factors, indicating the potential of YTHDC2 as a therapeutic target for breast cancer patients. Here, YTHDC2 is linked to breast carcinoma.